Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

robalzotan

Known as: 3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen tartrate monohydrate 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzopyrans

Narrower (1)

NAD 299

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Synthesis of robalzotan, ebalzotan, and rotigotine precursors via the stereoselective multienzymatic cascade reduction of α,β-unsaturated aldehydes.
A stereoselective synthesis of bicyclic primary or secondary amines, based on tetralin or chroman structural moieties, is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2006
2006
Robalzotan (NAD‐299), a Novel Selective 5‐HT 1A Receptor Antagonist
5-Hydroxytryptamine (5-HT, serotonin) is widely distributed in the serotonergic neurons in the CNS with the cell bodies in the… Expand
  • figure 1
  • table 1
2005
2005
Central serotonergic control of cardiovascular reflexes.
Central serotonergic neurones control reflex parasympathetic outflow to the heart, airways and bladder in a number of species… Expand
  • figure 1.1
  • figure 3.14
  • figure 3.17
  • figure 5.1
  • figure 5.7
Highly Cited
2003
Highly Cited
2003
Selective 5-HT1A Antagonists WAY 100635 and NAD-299 Attenuate the Impairment of Passive Avoidance Caused by Scopolamine in the Rat
Systemic administration of the muscarinic-receptor antagonists atropine and scopolamine produces cognitive deficits in humans… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2003
2003
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain
RationaleThe serotonin 5-HT1A receptor has been ascribed a putative role in the pathophysiology and drug treatment of depression… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2000
2000
PET-Determination of Robalzotan (NAD-299) Induced 5-HT1A Receptor Occupancy in the Monkey Brain
The serotonin 5-hydroxytryptamine-1A (5-HT1A) receptor subtype is of central interest in research, particularly in the area of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
2000
2000
Robalzotan AstraZeneca.
  • H. A. Mucke
  • Current opinion in investigational drugs
  • 2000
    • Corpus ID: 46577360
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety… Expand
Review
2000
Review
2000
Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development.
Positron-emission tomography (PET) provides potential in neuropsychiatric drug development by expanding knowledge of drug action… Expand
1999
1999
The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing.
5-HT(1A) receptor antagonists have been suggested to increase the efficacy of selective serotonin (5-hydroxytryptamine; 5-HT… Expand
1998
1998
Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.
In vitro receptor binding properties of the novel tritiated 5-hydroxytryptamine1A (5-HT1A) receptor antagonist (R)-3-N,N… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE